Schmitt M - Search Results

1

Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients.

Look M, van Putten W, Duffy M, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, Fred Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brünner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder M, Manders P, Edward Fiets W, Blankenstein M, Broët P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex L, Klijn J, O'Higgins N, Eppenberger U, Jänicke F, Schmitt M, Foekens J. Look M, et al. Among authors: schmitt m. Thromb Haemost. 2003 Sep;90(3):538-48. doi: 10.1160/TH-02-11-0264. Thromb Haemost. 2003. PMID: 12958624

2

Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.

Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Jänicke F, Klijn JG. Foekens JA, et al. Among authors: schmitt m. Cancer Res. 1992 Nov 1;52(21):6101-5. Cancer Res. 1992. PMID: 1394237

3

Tumor-associated urokinase-type plasminogen activator: biological and clinical significance.

Schmitt M, Jänicke F, Moniwa N, Chucholowski N, Pache L, Graeff H. Schmitt M, et al. Biol Chem Hoppe Seyler. 1992 Jul;373(7):611-22. doi: 10.1515/bchm3.1992.373.2.611. Biol Chem Hoppe Seyler. 1992. PMID: 1515091 Review.

4

[Flow cytometry DNA analysis of pure cell nuclei from formalin fixed paraffin sections in primary breast cancer: correlation with other prognostic factors].

Harbeck N, Moniwa N, Busch E, Schmitt M, Jänicke F, Fellbaum C, Höfler H, Graeff H. Harbeck N, et al. Among authors: schmitt m. Gynakol Rundsch. 1991;31 Suppl 2:299-302. Gynakol Rundsch. 1991. PMID: 1790958 German. No abstract available.

5

Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.

Jänicke F, Schmitt M, Graeff H. Jänicke F, et al. Among authors: schmitt m. Semin Thromb Hemost. 1991 Jul;17(3):303-12. doi: 10.1055/s-2007-1002624. Semin Thromb Hemost. 1991. PMID: 1796300 No abstract available.

6

Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.

Schmitt M, Goretzki L, Jänicke F, Calvete J, Eulitz M, Kobayashi H, Chucholowski N, Graeff H. Schmitt M, et al. Biomed Biochim Acta. 1991;50(4-6):731-41. Biomed Biochim Acta. 1991. PMID: 1801751

7

Human tumor cell urokinase-type plasminogen activator (uPA): degradation of the proenzyme form (pro-uPA) by granulocyte elastase prevents subsequent activation by plasmin.

Schmitt M, Kanayama N, Jänicke F, Hafter R, Graeff H. Schmitt M, et al. Adv Exp Med Biol. 1991;297:111-28. doi: 10.1007/978-1-4899-3629-5_10. Adv Exp Med Biol. 1991. PMID: 1837419

8

[Clinical and prognostic significance of tumor-associated proteases in gynecologic oncology].

Graeff H, Jänicke F, Schmitt M. Graeff H, et al. Among authors: schmitt m. Geburtshilfe Frauenheilkd. 1991 Feb;51(2):90-9. doi: 10.1055/s-2007-1023682. Geburtshilfe Frauenheilkd. 1991. PMID: 2040418 Review. German.

9

Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.

Schmitt M, Jänicke F, Graeff H. Schmitt M, et al. Blood Coagul Fibrinolysis. 1990 Dec;1(6):695-702. Blood Coagul Fibrinolysis. 1990. PMID: 2133250

10

Urokinase-type plasminogen activator antigen and early relapse in breast cancer.

Jänicke F, Schmitt M, Ulm K, Gössner W, Graeff H. Jänicke F, et al. Among authors: schmitt m. Lancet. 1989 Oct 28;2(8670):1049. doi: 10.1016/s0140-6736(89)91070-2. Lancet. 1989. PMID: 2572788 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,000 results

Search Page

Filters